文献速递乳腺癌

pT1ab淋巴结阴性三阴性乳腺癌的辅助化疗:一项全国多机构回顾性研究结果

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
PubMed 文献 · Eur J Cancer · 2017-08-04

该研究回顾性分析了15个法国中心1987至2013年间22,475例原发手术患者中284例pT1abN0M0导管型三阴性乳腺癌,其中144例(51%)接受辅助化疗、140例(49%)未接受。化疗与无病生存(HR=0.77,95%CI 0.40-1.46,p=0.419)和无转移生存(HR=1.00,95%CI 0.46-2.19,p=0.997)均无显著获益,5年DFS化疗组90%对未化疗组84%,5年MFS两组均为90%。结论未发现化疗的显著DFS或MFS优势。

要点

  • 284例pT1abN0M0导管型三阴性乳腺癌中,144例(51%)接受化疗,140例(49%)未接受。
  • 化疗与DFS无显著获益相关(HR=0.77,95%CI 0.40-1.46,p=0.419)。
  • 化疗与MFS无显著获益相关(HR=1.00,95%CI 0.46-2.19,p=0.997)。

核心结论

  • 本研究未发现辅助化疗在亚厘米、淋巴结阴性导管型三阴性乳腺癌中带来显著的无病生存或无转移生存优势。
  • 尽管当前共识指南推荐对所有大于5 mm的三阴性乳腺癌考虑化疗,鉴于获益未经证实,临床医生应与患者仔细讨论获益/风险比。

研究设计与样本

  • 回顾性研究,从1987至2013年间15个法国中心接受原发手术的22,475例患者队列中识别患者。
  • 仅纳入根据世界卫生组织(WHO)最新分类的浸润性导管癌非特殊型,最终分析284例pT1abN0M0导管型三阴性乳腺癌患者。
  • 终点为无病生存(DFS)和无转移生存(MFS),并采用倾向性评分(包含年龄、肿瘤大小、Scarff Bloom and Richardson(SBR)分级和淋巴血管侵犯的logistic回归)进行分析。

主要发现

  • 144例(51%)接受化疗,140例(49%)未接受化疗;接受化疗者具有更多不良预后特征,如肿瘤大小、高级别、年轻和淋巴血管侵犯。
  • 化疗与DFS无显著获益相关(HR=0.77 [0.40-1.46];p=0.419,log-rank检验)。
  • 化疗与MFS无显著获益相关(HR=1.00 [0.46-2.19];p=0.997)。
  • 5年DFS化疗组 vs 未化疗组为90% [81-94%] vs 84% [74-90%];5年MFS化疗组 vs 未化疗组为90% [81-95%] vs 90% [83%-95%]。
  • 结果在所有支持性分析中一致,包括多变量Cox模型以及使用倾向性评分进行调整和作为病例对照分析的匹配因素。

临床怎么用

  • 作者指出,尽管当前共识指南推荐对所有大于5 mm的三阴性乳腺癌考虑化疗,鉴于获益未经证实,临床医生应与患者仔细讨论获益/风险比。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancers (TNBCs) are considered as associated with poor outcome, but prognosis of subcentimetric, node-negative disease remains controversial and evidence that adjuvant chemotherapy (CT) is effective in these small tumours remains limited. PATIENTS AND METHODS: Our objective was to investigate the impact of CT on survival in pT1abN0M0 TNBC. Patients were retrospectively identified from a cohort of 22,475 patients who underwent primary surgery in 15 French centres between 1987 and 2013. As rare pathological types may display very particular prognoses in these tumours, we retained only the invasive ductal carcinomas of no special type according to the last World Health Organisation (WHO) classification which is the most common TNBC histological type. End-points were disease-free survival (DFS) and metastasis-free survival (MFS). A propensity score for receiving CT was estimated using a logistic regression including age, tumour size, Scarff Bloom and Richardson (SBR) grade and lymphovascular invasion. RESULTS: Of a total of 284 patients with pT1abN0M0 ductal TNBC, 144 (51%) received CT and 140 (49%) did not. Patients receiving CT had more adverse prognostic features, such as tumour size, high grade, young age, and lymphovascular invasion. CT was not associated with a significant benefit for DFS (Hazard ratio, HR = 0.77 [0.40-1.46]; p = 0.419, log-rank test) or MFS (HR = 1.00 [0.46-2.19]; p = 0.997), with 5-year DFS and MFS in the group with CT versus without of 90% [81-94%] versus 84% [74-90%], and 90% [81-95%] versus 90% [83%-95%], respectively. Results were consistent in all supportive analyses including multivariate Cox model and the use of the propensity score for adjustment and as a matching factor for case-control analyses. CONCLUSIONS: This study did not identify a significant DFS or MFS advantage for CT in subcentimetric, node-negative ductal TNBC. Although current consensus guidelines recommend consideration of CT in all TNBC larger than 5 mm, clinicians should carefully discuss benefit/risk ratio with patients, given the unproven benefits.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. de Nonneville A, Gonçalves A, Zemmour C, et al. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study. Eur J Cancer. 2017. PMID: 28780480. doi:10.1016/j.ejca.2017.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。